Thompson TC - Search Results

1

Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models.

Luo Y, Azad AK, Karanika S, Basourakos SP, Zuo X, Wang J, Yang L, Yang G, Korentzelos D, Yin J, Park S, Zhang P, Campbell JJ, Schall TJ, Cao G, Li L, Thompson TC. Luo Y, et al. Among authors: thompson tc. Int J Cancer. 2018 May 15;142(10):2163-2174. doi: 10.1002/ijc.31237. Epub 2018 Jan 30. Int J Cancer. 2018. PMID: 29277895 Free PMC article.

2

Transforming growth factor beta 1 as a biomarker for prostate cancer.

Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC, Scardino PT, Park SH. Thompson TC, et al. J Cell Biochem Suppl. 1992;16H:54-61. doi: 10.1002/jcb.240501212. J Cell Biochem Suppl. 1992. PMID: 1289674 Review.

3

Experimental oncogene induced prostate cancer.

Thompson TC, Kadmon D, Timme TL, Merz VW, Egawa S, Krebs T, Scardino PT, Park SH. Thompson TC, et al. Cancer Surv. 1991;11:55-71. Cancer Surv. 1991. PMID: 1726789

4

The frequency of apoptosis correlates with the prognosis of Gleason Grade 3 adenocarcinoma of the prostate.

Aihara M, Scardino PT, Truong LD, Wheeler TM, Goad JR, Yang G, Thompson TC. Aihara M, et al. Among authors: thompson tc. Cancer. 1995 Jan 15;75(2):522-9. doi: 10.1002/1097-0142(19950115)75:2<522::aid-cncr2820750215>3.0.co;2-w. Cancer. 1995. PMID: 7529128

5

Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer.

Thompson TC, Park SH, Timme TL, Ren C, Eastham JA, Donehower LA, Bradley A, Kadmon D, Yang G. Thompson TC, et al. Oncogene. 1995 Mar 2;10(5):869-79. Oncogene. 1995. PMID: 7534899

6

DNA ploidy and clonal selection in ras + myc-induced mouse prostate cancer.

Greene DR, Taylor SR, Aihara M, Yoshida K, Egawa S, Park SH, Timme TL, Yang G, Scardino PT, Thompson TC. Greene DR, et al. Among authors: thompson tc. Int J Cancer. 1995 Jan 27;60(3):395-9. doi: 10.1002/ijc.2910600321. Int J Cancer. 1995. PMID: 7829250

7

Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras+myc-induced carcinomas in the mouse prostate reconstitution model system.

Slawin K, Kadmon D, Park SH, Scardino PT, Anzano M, Sporn MB, Thompson TC. Slawin K, et al. Among authors: thompson tc. Cancer Res. 1993 Oct 1;53(19):4461-5. Cancer Res. 1993. PMID: 8402613

8

Transgenic models for the study of prostate cancer.

Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC, Scardino PT, Park SH. Thompson TC, et al. Cancer. 1993 Feb 1;71(3 Suppl):1165-71. doi: 10.1002/1097-0142(19930201)71:3+<1165::aid-cncr2820711440>3.0.co;2-u. Cancer. 1993. PMID: 8428340 Review.

9

Retroviral transduction of transforming growth factor-beta1 induces pleiotropic benign prostatic growth abnormalities in mouse prostate reconstitutions.

Timme TL, Yang G, Rogers E, Kadmon D, Morganstern JP, Park SH, Thompson TC. Timme TL, et al. Among authors: thompson tc. Lab Invest. 1996 Apr;74(4):747-60. Lab Invest. 1996. PMID: 8606485

10

Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models.

Eastham JA, Chen SH, Sehgal I, Yang G, Timme TL, Hall SJ, Woo SL, Thompson TC. Eastham JA, et al. Among authors: thompson tc. Hum Gene Ther. 1996 Mar 1;7(4):515-23. doi: 10.1089/hum.1996.7.4-515. Hum Gene Ther. 1996. PMID: 8800746

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

261 results

Search Page

Filters